Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Theodore Steven Lawrence

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4186-8821; OpenAlex author ID A5046132413; NIH RePORTER profile ID 1863924. Sources: OpenAlex.

Their work

Papers
30 (first author 1, last author 2)
Trials
0
Grants
6
Labs led
1
Collaborators
85
Papers, trials and grants by year

2011: 2 papers · 2012: 6 papers · 2013: 4 papers · 2014: 3 papers · 2015: 1 grant · 2016: 1 grant · 2017: 2 papers · 2018: 1 paper, 1 grant · 2019: 2 papers · 2020: 4 papers · 2021: 2 papers, 1 grant · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 grants

Papers 30

  1. Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-24-0210↗
  2. Potentiating the radiation-induced type I interferon antitumoral immune response by ATM inhibition in pancreatic cancer. Co-author DOI 10.1172/jci.insight.168824↗
  3. Predictors of Acute and Late Toxicity in Patients Receiving Chemoradiation for Unresectable Pancreatic Cancer. Co-author DOI 10.1016/j.adro.2023.101266↗
  4. DNA-PK Inhibition and Radiation Promote Antitumoral Immunity through RNA Polymerase III in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-21-0725↗
  5. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Da… Co-author DOI 10.1097/sla.0000000000003242↗
  6. Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-20-0365↗
  7. Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resec… Co-author DOI 10.1016/j.ijrobp.2019.08.057↗
  8. UAE1 inhibition mediates the unfolded protein response, DNA damage and caspase-dependent cell death in pancreatic cancer. Co-author DOI 10.1016/j.tranon.2020.100834↗
  9. Tumour-reprogrammed stromal BCAT1 fuels branched-chain ketoacid dependency in stromal-rich PDAC tumours. Co-author DOI 10.1038/s42255-020-0226-5↗
  10. Expansion of Circulating Tumor Cells from Patients with Locally Advanced Pancreatic Cancer Enable Patient Derived Xenografts and Functional Studies for Persona… Co-author DOI 10.3390/cancers12041011↗
  11. Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. Co-author DOI 10.1158/0008-5472.can-19-0761↗
  12. Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic C… Last author DOI 10.1200/jco.19.00730↗
  13. Prognostic Value of c-MET Expression in Patients With Pancreatic Cancer Receiving Adjuvant and Neoadjuvant Chemoradiation Therapy. Co-author DOI 10.1016/j.ijrobp.2017.10.030↗
  14. Quantitative Proteomic Analysis of Serum Exosomes from Patients with Locally Advanced Pancreatic Cancer Undergoing Chemoradiotherapy. Co-author DOI 10.1021/acs.jproteome.7b00024↗
  15. Definitive Chemoradiation With Full-dose Gemcitabine for Unresectable Pancreatic Cancer: Efficacy of Involved-Field Radiotherapy. Co-author DOI 10.1097/coc.0000000000000200↗
  16. A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Co-author DOI 10.1016/j.tranon.2014.07.005↗
  17. ATDC/TRIM29 phosphorylation by ATM/MAPKAP kinase 2 mediates radioresistance in pancreatic cancer cells. Co-author DOI 10.1158/0008-5472.can-13-2289↗
  18. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-1038↗
  19. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Co-author DOI 10.1002/cncr.28117↗
  20. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiati… Co-author DOI 10.1016/j.ijrobp.2012.11.020↗
  21. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. Co-author DOI 10.1158/1078-0432.ccr-12-3748↗
  22. HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s. Co-author DOI 10.1158/1078-0432.ccr-13-0621↗
  23. Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2011.08.022↗
  24. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pa… Co-author DOI 10.1016/j.ijrobp.2012.02.051↗
  25. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Co-author DOI 10.1158/0008-5472.can-11-2866↗
  26. Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. Co-author DOI 10.1158/1535-7163.mct-12-0098↗
  27. Radiotherapy improves survival in unresectable pancreatic cancer: small trial but big (and credible) results. Last author DOI 10.1200/jco.2011.40.9771↗
  28. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. Co-author DOI 10.1593/neo.12538↗
  29. Radiotherapy: the importance of local control in pancreatic cancer. First author DOI 10.1038/nrclinonc.2011.182↗
  30. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Co-author DOI 10.4161/cc.10.24.18661↗

Grants 6

  1. Molecularly Targeted Radiosensitization of Locally Advanced Cancers P50CA269022↗
  2. Targeting Stromal Influences on BCKA Addiction in PDAC Tumors R01CA271369↗
  3. Sensitization to Chemoradiation by Therapeutic Targeting of the DNA Damage Response U01CA216449↗
  4. SARRP for Multimodality Image-Guided Stereotactic Irradiation S10OD025046↗
  5. Translational Research in GI Cancer P50CA130810↗
  6. Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer R01CA138723↗

Closest collaborators

The 25 strongest of 85 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Meredith Ann Morgan · 16 shared papers, 1 shared grant, 2011–2026 · strength 2.63
  2. Sunitha Nagrath · 2 shared papers, 1 shared grant, 2020–2026 · strength 1.19
  3. Deepak Nagrath · 1 shared paper, 1 shared grant, 2020–2026 · strength 1.09
  4. Leslie A. Parsels · 10 shared papers, 2011–2025 · strength 0.90
  5. Vaibhav Sahai · 6 shared papers, 2019–2025 · strength 0.81
  6. Kyle Clifford Cuneo · 7 shared papers, 2014–2023 · strength 0.66
  7. Mark M. Zalupski · 9 shared papers, 2012–2020 · strength 0.49
  8. Qiang Zhang · 3 shared papers, 2022–2025 · strength 0.49
  9. David M. Karnak · 6 shared papers, 2012–2025 · strength 0.44
  10. Jonathan Maybaum · 5 shared papers, 1 shared grant, 2011–2019 · strength 0.42
  11. Diane M. Simeone · 7 shared papers, 1 shared grant, 2012–2017 · strength 0.40
  12. Timothy L. Frankel · 3 shared papers, 2019–2022 · strength 0.36
  13. Victoria M. Valvo · 2 shared papers, 2024–2025 · strength 0.35
  14. Edgar Ben‐Josef · 8 shared papers, 2011–2018 · strength 0.35
  15. Alnawaz Rehemtulla · 4 shared papers, 2012–2025 · strength 0.34
  16. Hari Nathan · 3 shared papers, 2019–2021 · strength 0.33
  17. Clifford S. Cho · 3 shared papers, 2019–2021 · strength 0.33
  18. Filip Bednar · 2 shared papers, 2021–2023 · strength 0.33
  19. Carl G. Engelke · 4 shared papers, 2013–2021 · strength 0.29
  20. Jiaqi Shi · 3 shared papers, 2019–2020 · strength 0.26
  21. Qiang Zhang · 2 shared papers, 2019–2021 · strength 0.21
  22. Sarah Owen · 2 shared papers, 2020 · strength 0.19
  23. Rishi Das · 1 shared paper, 2023 · strength 0.18
  24. Eileen S. Carpenter · 1 shared paper, 2025 · strength 0.18
  25. Ines Lohse · 2 shared papers, 2017–2020 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.